India CRDMOs: Expert call takeaways: Trust and tech led execution, China+1 shift visible by 2027 and peptide complexities

Research evidence excerpt

India CRDMOs: Expert call takeaways: Trust and tech led execution, China+1 shift visible by 2027 and peptide complexities

J P M O R G A N Asia Pacific Equity Research

13 July 2026

India CRDMOs

Expert call takeaways: Trust and tech led execution,

China+1 shift visible by 2027 and peptide complexities

We hosted three experts to discuss India’s CRDMO outlook; below are our Pharmaceuticals & Healthcare

takeaways on the shift towards a capability and trust-led model, what could Services

accelerate China+1 reallocation (with impacts potentially clearer around 2027), Bansi Desai, CFA AC

and why peptide manufacturing in particular is defined by execution complexity (91 22) 6157 3581

and purification constraints. (detailed takeaways inside). bansi.desai@jpmorgan.com

Amlan Jyoti Das

• Anthem Biosciences (Ganesh Sambasivam): Anthem’s remarks reinforced (91 22) 6157 3574

how India’s CRDMO rise has been anchored in trust, moving from chemistry- amlan.das@jpmchase.com

led FTE outsourcing to higher-value, IP-sensitive process work as J.P.Tower,MorganSantacruz(E),India PrivateMumbaiLimited,- 400098,J.P. MorganSEBI

confidentiality, IP protection and regulatory execution proved out. They Registration: INH000001873, (91-22) 6157-3000.

argued that small molecules remain the backbone even for newer modalities

such as peptides, ADCs and oligos, and positioned technology-led process

development as the differentiator, using flow chemistry and biocatalysis to

make routes safer, greener, more controllable and faster to scale. A nitration

case study illustrated the impact: shifting from batch to a flow setup

compressed a roughly 5 ton campaign from about 3.5 months to around 35

days, while ADC capability was framed around linker and payload supply,